Do you give chemotherapy to women with clinical features of high risk ER+ breast cancer, but a low Oncotype DX score?
I wouldn't consider chemotherapy in this patient but some would. I will try to briefly summarize the arguments on both sides.
- Prior to oncotype, we made the decision about chemo based on anatomic risk alone. If the risk of recurrence was predicted to be 10% or greater, guidelines suggested chemoth...
I agree with Dr. @Dr. First Last's response for this T2N0 tumor; what gets more complicated is truly clinical high risk disease such as node-positive. While it is true that few 35 year olds were included in the trial, and estrogen sensitivity differs in pre- and post-menopausal breast cancer, it doe...
I agree with my colleagues above. Genomic tests such as the 21 gene assay appear when low risk to select for disease which has a more benign hormonally driven biology.
The fascinating question in a younger woman is whether the adjustments of the 21 gene assay based on TAILORx (chemo benefit in the 1...